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Background: Nitric oxide (NO) is endogenously synthesized from L-arginine and L-citrulline. Due to its effects on
nitric oxide synthase (NOS), reduced glutathione (GSH) may protect against the oxidative reduction of NO. The
present study determined the effectiveness of L-citrulline and/or GSH on markers indicative of NO synthesis in
in vivo conditions with rodents and humans and also in an in vitro condition.
Methods: In phase one, human umbilical vein endothelial cells (HUVECs) were treated with either 0.3 mM L-citrulline,
1 mM GSH (Setria®) or a combination of each at 0.3 mM. In phase two, Sprague–Dawley rats (8 weeks old) were
randomly assigned to 3 groups and received either purified water, L-citrulline (500 mg/kg/day), or a combination of
L-citrulline (500 mg/kg/day) and GSH (50 mg/kg/day) by oral gavage for 3 days. Blood samples were collected and
plasma NOx (nitrite + nitrate) assessed. In phase three, resistance-trained males were randomly assigned to orally ingest
either cellulose placebo (2.52 g/day), L-citrulline (2 g/day), GSH (1 g/day), or L-citrulline (2 g/day) + GSH (200 mg/day)
for 7 days, and then perform a resistance exercise session involving 3 sets of 10-RM involving the elbow flexors. Venous
blood was obtained and used to assess plasma cGMP, nitrite, and NOx.
Results: In phase one, nitrite levels in cells treated with L-citrulline and GSH were significantly greater than control
(p < 0.05). In phase two, plasma NOx with L-citrulline + GSH was significantly greater than control and L-citrulline
(p < 0.05). In phase three, plasma cGMP was increased, but not significantly (p > 0.05). However, nitrite and NOx for
L-citrulline + GSH were significantly greater at 30 min post-exercise when compared to placebo (p < 0.05).
Conclusions: Combining L-citrulline with GSH augments increases in nitrite and NOx levels during in vitro and
in vivo conditions.
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Also known as endothelium-derived relaxing factor
(EDRF), nitric oxide (NO) is biosynthesized endogenously
from L-arginine and oxygen, by various nitric oxide
synthase (NOS) enzymes and by reduction of inorganic
nitrate [1]. Cell types containing NOS have been demon-
strated to be able to reutilize L-citrulline, the byproduct of
NO synthesis, to L-arginine by the arginine-citrulline cycle
[2]. Nitric oxide is a gaseous signaling molecule which ac-
tivates soluble guanylate cyclase (sGC) in smooth muscle* Correspondence: darryn_willoughby@baylor.edu
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unless otherwise stated.cells, thereby catalyzing cyclic guanosine monophosphate
(cGMP) synthesis. Intracellular cGMP serves as a cellular
messenger and plays a role in a variety of biological pro-
cesses, and in human blood vessels, results in vasodilation
[3]. Cell types containing NOS have been demonstrated to
be able to reutilize L-citrulline, the byproduct of NO syn-
thesis, to L-arginine by the arginine-citrulline cycle [2].
An elevation in plasma L-arginine has been shown to im-
prove endothelial function because the vascular endothe-
lium uses NO to signal the surrounding smooth muscle to
relax, thus resulting in vasodilation and increasing blood
flow [4]. During exercise, vasodilation occurs as a result of
various intracellular events, including the production and
release of NO. However, it has recently been shown thatn Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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while effective in elevating plasma L-arginine and NO me-
tabolites nitrite and nitrate (NOx) after exercise, was inef-
fective at increasing blood flow during exercise [5].
L-citrulline has been indicated to be a second NO donor
in the NOS-dependent pathway, since it can be converted
to L-arginine [6]. Dietary L-citrulline supplementation has
shown conflicting results regarding its effectiveness at im-
proving exercise performance [7, 8]. Moreover, results
showing favorable effects in exercise performance [8] did
not assess NO status; therefore, this response cannot be
related to an improvement in exercise performance. The
importance of L-citrulline towards ergogenic support is
based on the premise that L-citrulline is not subject to
pre-systemic elimination and, consequently, could be
a more efficient way to elevate extracellular levels of
L-arginine. L-Citrulline can perhaps improve the effects
on nitrate elimination during the course of recovery from
exhaustive muscular exercise, and also serves as an effec-
tive precursor of L-arginine. It has been shown that three
grams daily of oral L-citrulline supplementation for seven
days elevated plasma L-arginine concentration and aug-
mented NO-dependent signaling [9].
Glutathione is a low molecular weight, water-soluble
tripeptide composed of the amino acids cysteine, glu-
tamic acid, and glycine. Glutathione is an important
antioxidant and plays a major role in the detoxification
of endogenous metabolic products, including lipid per-
oxides. Intracellular glutathione exists in both the oxi-
dized disulfide form (GSSG) or in reduced (GSH) state;
the ratio between GSH and GSSG is held in dynamic
balance depending on many factors including the tissue
of interest, intracellular demand for conjugation reac-
tions, intracellular demand for reducing power, and
extracellular demand for reducing potential. In some cell
types, GSH appears to be necessary for NO synthesis
and NO has been shown to be correlated with intracel-
lular GSH [10]. GSH stimulates total L-arginine turnover
and, in the presence of GSH, NOS activity is increased
[11]. This suggests that GSH may play an important role
in protection against oxidative reaction of NO, thus con-
tributing to the sustained release of NO. Therefore,
combining L-citrulline with GSH may augment the pro-
duction of NO. However, the effectiveness for oral GSH
supplementation in humans, particularly in combination
with L-citrulline has not been clearly delineated.
Using in vitro (cell culture) and in vivo approaches in
rodents and humans, the overall purpose of this study
was to determine the efficacy of L-citrulline and/or GSH
supplementation towards increasing the levels of cGMP,
nitrite, and NOx. We hypothesized that the combination
of L-citrulline and GSH would preferentially increase
the concentrations of cGMP, nitrite, and NOx levels
when compared to control conditions.Methods and procedures
L-citrulline and GSH (Setria®) used in each phase were
obtained from KYOWA HAKKO BIO CO., LTD (Tokyo,
Japan).
Phase 1 (in vitro efficacy study)
Human umbilical vein endothelial cells (HUVECs) were
purchased from Clonetics (San Diego, CA, USA) and cul-
tured in EGM-2 Bullet Kit medium (Clonetics) supple-
mented with 2 % fetal bovine serum (FBS) and complete
endothelial growth factors at 37 ° C in humidified 5 %
CO2. The cells were seeded into twenty-four well plates
5000 cells/cm2, and sub-confluent cell monolayers were
used for experiments. A subset of sub-confluent HUVECs
were used as controls and the remainder were treated with
either 0.3 mM L-citrulline, 1 mM GSH, or a combination
of each at 0.3 mM, and incubated for 24 h. To measure
nitrite production by HUVECs, the culture medium was
collected and centrifuged to remove any precipitated ma-
terials. Four wells for each condition were used and nitrite
concentrations of supernatants from each well were deter-
mined by high performance liquid chromatography
(HPLC) (ENO-20; Eicom, Kyoto, Japan) using our pre-
vious approach [12].
Phase 2 (rodent efficacy study)
This phase of the study was conducted in accordance
with the guidelines for the Institutional Animal Care
and Use Committee of KYOWA HAKKO BIO CO.,
LTD. Twenty-three male Sprague–Dawley rats (8 weeks
old; Japan SLC, Hamamatsu, Japan) were given free ac-
cess to standard rat chow (CE-2, CLEA JAPAN Inc.,
Tokyo, Japan) and tap water in a room with controlled
temperature (22 ± 2 ° C), humidity (55 ± 5 %) and a 12-h
light/dark cycle. After the rats had been anesthetized
with pentobarbital sodium (30 mg/kg, i.p.), a catheter
was inserted into the carotid artery. Following 3 days
of acclimation, the rats were randomly assigned to 3
groups and received either purified water (CON) (n = 7),
L-citrulline (500 mg/kg/day) (n = 8), or a combination of
L-citrulline (500 mg/kg/day) plus GSH (50 mg/kg/day)
(n = 8) by oral gavage for 3 days. Blood samples were
collected from the catheter at baseline and at 0, 0.25,
0.5, 1, 2, and 4 h after the last administration on Day 3.
Plasma NOx (nitrite + nitrate) was measured by HPLC
(ENO-20; Eicom, Kyoto, Japan) using our previous ap-
proach [12].
Phase 3 (human efficacy study)
Participants
Sixty-six apparently healthy, resistance trained [regular,
consistent resistance training (i.e., thrice weekly) for at
least one year prior to the onset of the study], males
between the ages of 18–30 and a body mass index
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double-blind, randomized, placebo-controlled, parallel-
groups study. Enrollment was open to men of all eth-
nicities. During the course of the study, six dropped out
due to reasons unrelated to the study. As a result, 60
participants completed the study. The age, height, and
body mass of participants in each of the four groups can
be seen in Table 1. Only participants considered as low
risk for cardiovascular disease and with no contraindica-
tions to exercise as outlined by the American College of
Sports Medicine (ACSM) and who had not consumed
any nutritional supplements (excluding multi-vitamins)
one month prior to the study were allowed to partici-
pate. All participants provided written informed consent
and were cleared for participation by passing a man-
datory medical screening. All eligible subjects signed
university-approved informed consent documents and ap-
proval was granted by the Baylor University Institutional
Review Board for the Protection of Human Subjects in
Research. Additionally, all experimental procedures in-
volved in the study conformed to the ethical consideration
of the Declaration of Helsinki.Entry and familiarization session (visit 1)
Individuals expressing interest in participating in the study
were interviewed on the telephone and/or e-mail to deter-
mine whether they appeared to qualify to participate in
the study. Participants believed to meet eligibility criteria
were then invited to attend an entry/familiarization ses-
sion (visit 1). Once reporting to the lab, individuals were
familiarized to the study protocol via a verbal and written
explanation outlining the study design and signed an in-
formed consent document. At this point, participants
completed a medical history questionnaire and underwent
a general physical examination to determine whether
they met eligibility criteria. Participants also performed a
muscle strength test of the elbow flexors (biceps), and
were then given an appointment time to report to the
laboratory for a baseline blood sample (visit 2). At this
time, participants were instructed to refrain from exercise
for 48 h and fast for 8 h prior to baseline blood sampling
(visit 2) and post-supplementation testing at day 7 (visit 3).Table 1 Age, height, and body mass of participants in each of
the four groups
Group Age (yrs) Height (cm) Body mass (kg)
PLC (n = 15) 21.80 ± 0.92 179.52 ± 2.10 83.92 ± 6.65
GSH (n = 15) 22.67 ± 0.97 179.90 ± 1.71 83.42 ± 2.92
CIT (n = 15) 21.07 ± 0.67 177.17 ± 1.55 80.46 ± 3.17
CIT + GSH (n = 15) 21.67 ± 0.56 179.03 ± 2.34 83.06 ± 2.79
Data are expressed as means ± SEMAssessment of elbow flexor muscle strength (visit 1)
In order to determine maximum muscular strength of the
elbow flexors, participants performed a one-repetition
maximum (1-RM) test on the same elbow flexor machine
used in the resistance exercise session based on our pre-
vious study [5]. Participants warmed up by completing 5
to 10 repetitions at approximately 50 % of the estimated
1-RM. The participant rested for 1 min, and then com-
pleted 3 to 5 repetitions at approximately 70 % of the
estimated 1-RM. The weight was then increased conserva-
tively, and the participant attempted to lift the weight for
one repetition. If the lift was successful, the participant
rested for 2 min before attempting the next weight incre-
ment. This procedure was continued until the participant
failed to complete the lift. The 1-RM was recorded as the
maximum weight that the participant was able to lift for
one repetition.
Resistance exercise protocol (visit 3, day 7)
Based on our previous study [5], on day 7 participants
reported to the Exercise and Biochemical Nutrition Lab
at approximately 2:00 pm and performed 3 sets of 15
repetitions with as much weight as they could lift per set
(typically 70–75 % of 1RM) involving the elbow flexion
exercise on a selectorized weight machine (Body Master,
Rayne, LA). Rest periods between sets were timed and
lasted exactly 10 s. The resistance exercise session was per-
formed under the direct supervision of study personnel.
Venous blood sampling (visit 2, day 0 and visit 3, day 7)
Venous blood samples were obtained from the antecubi-
tal vein into 10 ml serum and plasma collection tubes
using a standard vacutainer apparatus. Blood samples
were allowed to stand at room temperature for 10 min
and then centrifuged. The serum and plasma was re-
moved and frozen at −80 °C for later analysis. One base-
line blood sample was obtained at visit 2 and 3 samples
were obtained at visit 3 (for a total of 4 blood samples).
At visit 3 on day 7, the first sample was obtained imme-
diately before ingesting the supplement, the second sam-
ple was obtained immediately after resistance exercise,
and the third sample 30 min following exercise (Fig. 1).
Supplementation protocol
In a randomized, double-blind fashion participants were
randomly assigned to one of four groups (n = 15 per
group) involving 7 days of the oral ingestion of four cap-
sules containing a total daily dose of either: cellulose pla-
cebo (2.52 g/day), L-citrulline (2 g/day), GSH (1 g/day),
or L-citrulline (2 g/day) + GSH (200 mg/day). The total
weight of the four capsules for each group was the same.
Each participant ingested all four capsules containing
their respective daily supplement dose each evening for
six consecutive days. At Visit 3 (Day 7), participants
Fig. 1 An illustration of the experimental protocol for the testing session at visit 3, following seven days of L-citrulline and/or GSH supplementation
Fig. 2 From phase one, an illustration of nitrite concentration in
HUVECs following supplementation with L-citrulline and/or GSH.
The symbol * indicates that cells supplemented with a combination
of L-citrulline (CIT) and GSH underwent significant increases in nitrite
formation compared to cells supplemented with phosphate buffered
saline (CON) (p < 0.05)
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supplement ingested one hour prior to performing the
resistance exercise. Supplementation compliance was
monitored by participants returning empty containers of
their supplement on day 7, and also by completing a
supplement compliance questionnaire.
Assessment of blood variables (L-citrulline and L-arginine)
To determine plasma L-citrulline and L-arginine con-
centrations, the plasma was de-proteinated by mixing
equal volumes of plasma and trichloroacetic acid (TCA)
(6.0 % wt/vol). The samples were vortexed and cen-
trifuged for 15 min at 12,000 × g. Amino acids in the
supernatant were analyzed with an amino acid analyzer
(L-8900, Hitachi, Japan).
Assessment of plasma cGMP and nitrite
From the blood samples obtained at visit 2 (day 0) and
visit 3 (day 7), using commercially-available enzyme-
linked immunoabsorbent assay (ELISA) kits (Cayman
Chemical, Ann Arbor, MI, USA), plasma cGMP, nitrite,
and NOx were determined. Assays were analyzed in du-
plicate and absorbances for each variable were deter-
mined at a wavelength of 450 nm using a microplate
reader (iMark, Bio-Rad, Hercules, CA). A set of stan-
dards of known concentrations for each variable utilized
to construct standard curves and concentrations were
determined using data reduction software (Microplate
Manager, Bio-Rad, Hercules, CA).
Statistical analysis
For in vitro (phase 1), rodent (phase 2), and the human
(phase 3) efficacy studies, results were expressed as mean
± SEM. Delta values (differences between the baseline and
sequential values) were analyzed using Bonferroni’s test
following one-way ANOVA. For multiple comparisons to
identify the statistical differences among treatments, the
Bonferroni correction or Dunnett’s multiple test following
a comparison of the data by non-repeated ANOVA was
employed. Statistical significance was considered as ap-value ≤ 0.05. Statistical analysis was performed using
Statcel software for Windows (Version 2, OMS Publishing,
Inc., Saitama, Japan) and the Systat 2000 Statistical
Program File (Igaku Tosho Shuppan, Tokyo, Japan).Results
Phase 1 (in-vitro cell culture study)
Results demonstrated no significant differences between
the control condition and cells treated with L-citrulline
and GSH (p > 0.05) for nitrite concentration. However,
cells treated with L-citrulline and GSH were significantly
greater than control-treated cells (p < 0.05) (Fig. 2).Phase 2 (rodent efficacy study)
For plasma NOx delta values, results demonstrated that
L-citrulline + GSH was significantly greater than control
and L-citrulline at one hr post-supplement infusion
(p < 0.05) (Fig. 3).
Fig. 3 From phase two, an illustration of plasma NOx levels in rats
following supplementation with L-citrulline and/or GSH. The symbols *
and # indicate that combined L-citrulline (CIT) and GSH-supplemented
rats underwent significant increases in plasma NOx at one hr following
supplement infusion compared to animals supplemented with water
(CON) and CIT, respectively (p < 0.05)
Fig. 4 From phase three, an illustration of plasma arginine levels in
humans following seven days of supplementation with L-citrulline
and/or GSH. Results indicated that L-citrulline (CIT) and a combination of
CIT + GSH produced significant increases in plasma arginine immediately
after and 30 min post-exercise compared to groups supplemented
with cellulose (PLC) and GSH. The symbol * indicates a significant
increase compared to PLC and the symbol † indicates a significant
increase compared to GSH (p < 0.05)
Fig. 5 From phase three, an illustration of plasma citrulline levels in
humans following seven days of supplementation with L-citrulline
and/or GSH. Results indicated that L-citrulline (CIT) and a combination
of CIT + GSH produced significant increases in plasma CIT immediately
after and 30 min post-exercise compared to groups supplemented
with cellulose (PLC) and GSH. The symbol * indicates a significant
increase compared to PLC and the symbol † indicates a significant
increase compared to GSH (p < 0.05)
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Plasma L-arginine and L-citrulline
Since no supplementation was involved at the baseline
testing session, as expected, no significant differences
between groups or time points (p > 0.05) for plasma
L-citrulline and L-arginine were observed. However, at the
follow-up testing session following seven 7 days of supple-
mentation significant increases for plasma L-arginine and
L-citrulline were noted. For L-arginine, no significant dif-
ferences occurred between placebo and GSH at any time
points (p > 0.05). However, at the immediate post-exercise
time point L-citrulline was significantly greater than pla-
cebo and GSH, whereas L-citrulline + GSH was greater
than GSH (p < 0.05). In addition, at 30 min post-exercise
L-citrulline and L-citrulline + GSH were both significantly
greater than placebo and GSH (p < 0.05) (Fig. 4). For
plasma L-citrulline, L-citrulline and L-citrulline + GSH
were both significantly greater than placebo and GSH
immediately post-exercise and at 30 min post-exercise
(p < 0.05) (Fig. 5).
Plasma cGMP, nitrite, and NOx
The delta values for the plasma levels of cGMP, nitrite,
and NOx can be seen in Figs. 6, 7 and 8, respectively.
For cGMP (Fig. 6), L-citrulline + GSH was elevated com-
pared to the other three groups, but there were no sig-
nificant differences between groups and time points
observed (P > 0.05). For nitrite (Fig. 7) and NOx (Fig. 8),
L-citrulline + GSH was significantly greater than placebo
at 30 min post-exercise (P < 0.05).
Discussion
In the present study, we sought to determine the effec-
tiveness of L-citrulline and/or GSH in increasing NO
synthesis during in vivo conditions with rodents and
humans and also in an in vitro condition using HUVEC.Collectively, in phase one and three of the study we ob-
served combining L-citrulline with GSH to be more ef-
fective at increasing the concentrations of nitrite and/or
NOx than with control/placebo in HUVEC and humans,
respectively. In phase two, we observed L-citrulline com-
bined with GSH to be more effective at increasing
plasma NOx.
L-citrulline is a ubiquitous amino acid in mammals
[13], and in the kidneys, vascular endothelium, and other
tissues can be readily converted to L-arginine thus
Fig. 6 From phase three, an illustration of plasma cGMP levels in
humans following seven days of supplementation with L-citrulline
and/or GSH. Results indicated no significant differences between any
of the groups at any of the assessed time points (p > 0.05)
Fig. 8 From phase three, an illustration of plasma NOx levels in
humans following seven days of supplementation with L-citrulline
and/or GSH. The symbol * indicates that a combination of L-citrulline
(CIT) and GSH produced significant increases in plasma NOx at 30 min
post-exercise compared to the group supplemented with cellulose
placebo (PLC) (p < 0.05)
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creases NOS synthesis and subsequent NO production
[14]. Additionally, L-citrulline has been indicated to be a
secondary NO donor in the NOS-dependent pathway,
since it can be converted to L-arginine. Nitrate and
nitrite are the main substrates to produce NO via the
NOS-independent pathway. These anions can be re-
duced in vivo to NO and other bioactive nitrogen
oxides.
Previous studies have reported that L-citrulline
could increase plasma L-arginine concentration by the
L-citrulline-NO cycle [15]. Fu et al. [16] showed that
pre-treatment with L-citrulline in rodents for seven days
at doses of 300, 600, and 900 mg/kg increased the NO
content. Since L-citrulline can be readily converted to
L-arginine, it provides a recycling pathway for the con-
version of L-citrulline to NO via L-arginine [14, 17]. In
phase three of the present study, we observed seven days
of L-citrulline supplementation, with and without
GSH, to result in significant increases in the levels of
plasma citrulline and arginine. Our present data supportFig. 7 From phase three, an illustration of plasma nitrite levels in
humans following seven days of supplementation with L-citrulline
and/or GSH. The symbol * indicates that a combination of L-citrulline
(CIT) and GSH produced significant increases in plasma nitrite at
30 min post-exercise compared to the group supplemented with
cellulose placebo (PLC) (p < 0.05)previous results [18] showing that a 10-g oral bolus of
L-citrulline significantly enhanced plasma citrulline and
arginine levels compared with placebo. Therefore, our
present observations indicate that L-citrulline is indeed a
precursor to L-arginine formation which subsequently
increases circulating levels of NOx, and that recycling of
L-citrulline to L-arginine may maintain substrate con-
centration in favor of NO synthesis [19].
It has been shown in some mammalian cell types, that
GSH and NO activity are linked [20]. Furthermore, results
suggest that GSH is necessary in HUVEC for NO syn-
thesis rather than for the NO-related effect on guanylate
cyclase, because when cells were depleted of GSH, cit-
rulline synthesis and cGMP production were inhibited in
a concentration-dependent manner [21]. This may be
explained based on the premise that the synthesis of NO,
detected as L-citrulline production, in HUVEC and mur-
ine endothelial cells has been shown to be correlated with
intracellular GSH [10]. A previous study suggested that in
some cell types, the activity of NO is influenced by the en-
dogenous antioxidant GSH [22]. It is conceivable that
GSH activity may be augmented by L-citrulline as it has
been shown that pre-treatment with L-citrulline in ro-
dents for seven consecutive days lead to an elevation in
the level of GSH [23].
Furthermore, in phase one of the present study, we
showed that combining L-citrulline and GSH effectively
increased nitrite concentration in HUVEC cells compared
to control; although, both L-citrulline and GSH alone had
no effect on nitrite. However, in phase two, the combined
L-citrulline and GSH provided to rodents resulted in a sig-
nificant increase in plasma NOx one hr following inges-
tion compared to control and L-citrulline. Moreover, we
observed a similar response in phase three compared to
phase one, where combining L-citrulline and GSH effect-
ively increased plasma nitrite and NOx concentration in
humans compared to placebo.
McKinley-Barnard et al. Journal of the International Society of Sports Nutrition  (2015) 12:27 Page 7 of 8Oral supplementation with L-arginine can increase
plasma L-arginine levels; although, oral supplementation
with L-citrulline, a precursor for arginine biosynthesis, has
been shown to be more efficient than oral L-arginine in
increasing plasma L-arginine [9], due to splanchnic cata-
bolism of ingested L-Arginine [24]. NO synthesis is prima-
rily dependent upon intracellular arginine availability and
is affected by: 1) the transport of extracellular arginine;
2) intracellular synthesis of arginine from citrulline, which
is dependent on citrulline availability; and 3) the activity of
arginase [17]. Moreover, this latter point can be further
supported based on the data demonstrating increased ar-
ginine availability in cultured cell model or by supplemen-
tation in vivo was able to overcome the effects of arginase
and to enhance NO synthesis [25]. Based on results from
all three phases of the present study, it is evident that
L-citrulline supplementation impacted extracellular ar-
ginine concentration and the subsequent intracellular
arginine synthesis based on the responses we observed in
nitrite and NOx concentrations.
In phase 3 of the present study, we were also inter-
ested to determine if increased plasma arginine availabil-
ity and subsequent NO synthesis due to oral L-citrulline
and/or GSH supplementation was effected by resistance
exercise. Interestingly, we observed increases in plasma
NOx in all four groups immediately following resistance
exercise, which indicates this response in plasma NOx
to be particularly due to the stimulus of resistance exer-
cise. These results are similar to our previous study
where resistance exercise increased plasma NOx, inde-
pendent of increased plasma arginine, due to seven days
of L-arginine supplementation [5]. In the same way as
NOx, plasma cGMP levels were increased by the com-
bination of L-citrulline and GSH; however, this increase
was not significantly different. Nevertheless, this sug-
gests a possible synergistic effect from GSH that may be
partially mediated by the formation of the NO-GSH
complex. However, in the present study, significantly dif-
ferent increases in NOx occurred 30 min following re-
sistance exercise, and only for the L-citrulline + GSH
group. This suggests that a resistance exercise-related
mechanism of inducing plasma NO, perhaps due to in-
creased shear stress that triggered an up-regulation in
NO-cGMP signaling, is a conceivable candidate for this
response.
Consequently, there are possible physiological benefits
of having high NO levels at 30 min post-exercise relative
to its impact on muscle protein metabolism and possible
muscle performance in response to resistance exercise
training. It has been shown that NOS activity is neces-
sary for calcium-induced activation of the Akt pathway
(involved in translation initiation and thus muscle pro-
tein synthesis), and that NO is sufficient to elevate Akt
activity in primary myotubes. Nitric oxide appears toinfluence Akt signaling though a cGMP/PI3K-dependent
pathway [26], which is the primary pathway for up-
regulating translation initiation and protein synthesis in
skeletal muscle. Additionally, nitrite has been shown to
enhance the proliferation and mTOR activity of myoblasts
[27]. Similarly, NO seems to influence skeletal muscle
function through effects on excitation-contraction coup-
ling, myofibrillar function, perfusion, and metabolism. An-
other study showed that by using an agent to inhibit
phosphodiesterase-5, that the augmentation of NO-cGMP
signaling increased protein synthesis and reduced fatigue
in human skeletal muscle [28]. In the present study,
L-citrulline + GSH showed an improvement in cGMP ac-
tivity suggesting that this outcome could likely play a role
in muscle protein synthesis and muscle performance when
combined with resistance training.
Our present data suggest that the oral supplementa-
tion of L-citrulline combined with GSH provides an aug-
menting effect on plasma NOx. Based on results from
recent studies, this may be explained based on the pre-
mise that in some cell types, the activity of NO is in-
fluenced by the endogenous antioxidant, GSH [10].
Therefore, GSH may play an important role in protec-
tion against oxidative reaction of NO, thus contributing
to the sustained release of NO.
Conclusions
Herein, we have presented in vitro and in vivo data dem-
onstrating the efficacy of combining L-citrulline and GSH
and the subsequent effects on NO synthesis and, collec-
tively, we conclude that the combination of L-citrulline
and GSH increases the levels of cGMP, nitrite, and NOx.
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